About: Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates
Creator	Roederer, Mario Balachandran, Harikrishnan Custers, Jerome Letvin, Norman Radošević, Katarina Santra, Sampa Song, Kaimei Bolton, Diane Kozlowski, Pamela Swett, Cindy
Source	Elsevier; Medline; PMC
abstract	Licensed live attenuated virus vaccines capable of expressing transgenes from other pathogens have the potential to reduce the number of childhood immunizations by eliciting robust immunity to multiple pathogens simultaneously. Recombinant attenuated measles virus (rMV) derived from the Edmonston Zagreb vaccine strain was engineered to express simian immunodeficiency virus (SIV) Gag protein for the purpose of evaluating the immunogenicity of rMV as a vaccine vector in rhesus macaques. rMV-Gag immunization alone elicited robust measles-specific humoral and cellular responses, but failed to elicit transgene (Gag)-specific immune responses, following aerosol or intratracheal/intramuscular delivery. However, when administered as a priming vaccine to a heterologous boost with recombinant adenovirus serotype 5 expressing the same transgene, rMV-Gag significantly enhanced Gag-specific T lymphocyte responses following rAd5 immunization. Gag-specific humoral responses were not enhanced, however, which may be due to either the transgene or the vector. Cellular response priming by rMV against the transgene was highly effective even when using a suboptimal dose of rAd5 for the boost. These data demonstrate feasibility of using rMV as a priming component of heterologous prime-boost vaccine regimens for pathogens requiring strong cellular responses.
has issue date	2012-09-01(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2012.06.029
bibo:pmid	22732429
has license	green-oa
sha1sum (hex)	89d3baf8c1fd705699fccd3512d167dd47375188
schema:url	https://doi.org/10.1016/j.vaccine.2012.06.029
resource representing a document's title	Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates
has PubMed Central identifier	PMC3425710
has PubMed identifier	22732429
schema:publication	Vaccine
resource representing a document's body	covid:89d3baf8c1fd705699fccd3512d167dd47375188#body_text
is schema:about of	named entity 'T-CELL' named entity 'transgenes' named entity 'vaccine' named entity 'transgene' named entity 'priming' named entity 'adenovirus' named entity 'Edmonston' named entity 'heterologous' named entity 'Gag' named entity 'vector' named entity 'protein' named entity 'response priming' named entity 'LICENSED' named entity 'T LYMPHOCYTE' named entity 'NUMBER OF' named entity 'POTENTIAL' named entity 'RESPONSES' named entity 'MEASLES' named entity 'PURPOSE' named entity 'SIMIAN IMMUNODEFICIENCY VIRUS' named entity 'HIGHLY' named entity 'MAY BE' named entity 'DOSE' named entity 'PATHOGENS' named entity 'COMPONENT' named entity 'CELLULAR' named entity 'PRIMATES' named entity 'BOOST' named entity 'VECTOR' named entity 'PRIMING' named entity 'RAD5' named entity 'IMMUNOGENICITY' named entity 'MEASLES VIRUS' named entity 'PRIME' named entity 'SETTING' named entity 'MEASLES VACCINE' named entity 'RECOMBINANT' named entity 'HETEROLOGOUS' named entity 'ENHANCED' named entity 'GAG PROTEIN' named entity 'TO REDUCE' named entity 'USING' named entity 'ROBUST' named entity 'MULTIPLE' named entity 'CELLULAR RESPONSE' named entity 'DELIVERY' named entity 'FOLLOWING' named entity 'DERIVED' named entity 'RECOMBINANT' named entity 'CHILDHOOD' named entity 'SPECIFIC' named entity 'HAVE' named entity 'IMMUNIZATIONS' named entity 'FAILED' named entity 'VACCINE STRAIN' named entity 'FEASIBILITY' named entity 'EITHER' named entity 'THESE' named entity 'RECOMBINANT ADENOVIRUS' named entity 'VACCINES' named entity 'ATTENUATED' named entity 'TO EXPRESS' named entity 'TRANSGENES' named entity 'CAPABLE' named entity 'RESPONSES' named entity 'IMMUNITY' named entity 'DATA' named entity 'RESPONSE PRIMING' named entity 'EVALUATING' named entity 'BOOST' named entity 'PRIMING' named entity 'BUT'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software